Program Leaders: Naomi Haas, MD and Kim Reiss, MD
The overall goal of the Cancer Therapeutics Program at the Abramson Cancer Center is to use mechanistic insights emerging from our basic science labs to improve cancer therapy for patients with advanced solid tumors. Cancer Therapeutics members accomplish this goal through three Specific Aims:
- Translate mechanistic biologic insights into Phase I trials
- Use data from Phase I trials to perform Phase II and Phase III trials to change clinical practice
- Discover and develop innovative biomarkers that enhance safety and efficacy of cancer therapies
The Program is co-led by Drs. Naomi Haas and Kim Reiss, who bring complementary scientific visions and a notable depth of experience as accomplished translational researchers. The Cancer Therapeutics Program encompasses a full range of basic, translational, and clinical research. Program members work on improving cancer therapies for patients with advanced, lethal, and often highly symptomatic solid tumors.
Cancer Therapeutics Program Membership
- Charu Aggarwal, MD, MPH
- Steven Albelda, MD
- Nduka Amankulor, MD
- Ravi Amaravadi, MD
- Stephen Bagley, MD, MSCE
- Devraj Basu, MD, PhD
- Erica Carpenter, MBA, PhD
- William Chapin, MD, MSCE
- Roger Cohen, MD
- Ahmed Diab, PhD
- Jennifer Eads, MD
- Evgeniy Eruslanov, PhD
- Saba Ghassemi, PhD
- Naomi Haas, MD
- Giorgos Karakousis, MD
- Thomas Karasic, MD
- Bonnie Ky, MD, MSCE
- Corey Langer, MD
- Gerald Linette, MD, PhD
- Leyuan Ma, PhD
- Melina Marmarelis, MD
- Michael Mitchell, PhD, MS
- Tara Mitchell, MD
- John Miura, MD
- Mark Morgan, MD
- Vivek Narayan, MD
- Peter O’Dwyer, MD
- Mark O'Hara, MD
- Christopher Rassekh, MD
- Kim Reiss Binder, MD
- Todd Ridky, MD, PhD
- Antonia Rotolo, MD, PhD
- Lynn Schuchter, MD
- Fiona Simpkins, MD
- David Vaughn, MD
- Heather Wachtel, MD, FACS
- Gregory Weinstein, MD
- Kathryn Wellen, PhD
- Xiaowei Xu, MD, PhD